Upadacitinib (Rinvoq) for Vitiligo: What We Know So Far
If you have been using Opzelura for body vitiligo and wondering whether there is something more practical for widespread patches — this is the drug people in that situation are watching closely.
Upadacitinib (brand name Rinvoq, made by AbbVie) is an oral JAK inhibitor. AbbVie submitted applications to the FDA and EMA for vitiligo approval in February 2026, following positive Phase 3 trial results published in late 2025. No approval has been granted yet, but the submission places it in the pipeline — and for vitiligo patients, the oral route matters in a way that is worth understanding.
Why oral matters for vitiligo
Opzelura (ruxolitinib cream) is already FDA-approved for vitiligo and works well for many patients — particularly on the face and neck. But it is a cream applied to affected skin, which creates practical limits: applying it to large areas is time-consuming, requires multiple tubes per month, and is expensive. The FDA approval limits use to body surface areas where topical application is feasible.
An oral JAK inhibitor bypasses that entirely. One pill, systemic coverage. For patients with widespread vitiligo on the torso, limbs, or scalp where topical application is impractical, this is the meaningful difference.
What upadacitinib is
Upadacitinib is a JAK1-selective inhibitor — it targets JAK1 preferentially compared to other JAK enzymes. It is already approved for several inflammatory conditions: rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, ulcerative colitis, and Crohn’s disease. The vitiligo indication would extend that list.
The mechanism relevant to vitiligo: JAK-STAT signaling — specifically the IFN-γ/CXCL10 pathway — plays a central role in the immune attack on melanocytes. Blocking JAK1 interrupts that signaling. This is the same logic behind topical ruxolitinib; oral upadacitinib applies it systemically.
What the Phase 3 data showed
AbbVie’s Phase 3 programme for vitiligo showed positive results, which is why the regulatory submissions followed. The primary endpoint used in vitiligo trials is typically F-VASI (Facial Vitiligo Area Scoring Index) and T-VASI (Total VASI), measuring how much repigmentation occurs over 24–52 weeks.
The Phase 3 programme (two trials: Rinvoq-V1 and Rinvoq-V2) reported results in late 2025. At 52 weeks, approximately 48% of patients receiving upadacitinib 15mg achieved T-VASI50 (50% or greater improvement in total body vitiligo area) compared with 11% on placebo. Facial repigmentation responses were higher. These are meaningful numbers - substantially stronger than what topical ruxolitinib produces on body vitiligo. The safety profile at the 15mg dose was consistent with what has been seen in atopic dermatitis trials.
The honest framing: “positive Phase 3” means the drug worked well enough for the FDA to consider it — it does not mean everyone who takes it will repigment fully or quickly.
How it compares to Opzelura
| Opzelura (ruxolitinib) | Upadacitinib (Rinvoq) | |
|---|---|---|
| Route | Topical cream | Oral tablet |
| Approved for vitiligo | Yes (FDA, 2022) | Pending (FDA/EMA submission Feb 2026) |
| Best suited for | Localised vitiligo, face/neck | Widespread vitiligo, body coverage |
| Coverage | Limited by application practicality | Systemic |
| Safety monitoring | Lower (minimal systemic absorption) | Higher (oral JAK class warnings apply) |
| Cost | High (topical specialty drug) | Likely high (established oral specialty drug) |
Neither drug is “better” in absolute terms — they suit different situations. A patient with facial vitiligo and no body involvement has a strong case for trying Opzelura first. A patient with widespread body vitiligo who has plateaued on topical treatment is the profile upadacitinib is most likely to benefit.
Safety: what the oral JAK class means
This is important. Topical ruxolitinib has minimal systemic absorption, which is why its safety profile is relatively clean. Oral JAK inhibitors work differently — they are systemically active, and the FDA has applied class-wide warnings to all oral JAK inhibitors following post-marketing data from tofacitinib (Xeljanz).
The warnings cover:
- Serious infections (including opportunistic infections, TB reactivation)
- Malignancy risk (lymphoma and other cancers, though absolute risk appears low)
- MACE (major adverse cardiovascular events, particularly in patients with existing cardiovascular risk factors)
- Thrombosis (blood clots)
These risks are real but need context. Upadacitinib has a substantial safety track record from its use in RA, atopic dermatitis, and IBD — conditions where patients have been on it for years. For most patients without significant cardiovascular or immune compromise risk factors, the benefit-risk calculation may well favour treatment. But this is not a drug to start without a thorough conversation with a rheumatologist or dermatologist experienced in JAK inhibitors.
Notably, the safety profile of upadacitinib in atopic dermatitis (another immune-driven skin condition) at doses of 15mg and 30mg daily is well-characterised. The vitiligo dose and duration will be established in the prescribing information upon approval.
Who might be a candidate
The profile most likely to benefit from upadacitinib, once approved:
- Widespread vitiligo covering large body surface areas where topical treatment is not practical
- Patients who have tried and plateaued on topical ruxolitinib or phototherapy
- Non-segmental vitiligo (the autoimmune type — JAK inhibitors target the autoimmune mechanism)
- No major cardiovascular risk factors or immunocompromise that would raise the safety calculus
It is not likely to be a first-line treatment — both because of cost and because patients with limited or facial-only vitiligo have effective topical options already. It fits better as a next step for patients who need systemic coverage.
What to do while waiting for approval
Nothing, necessarily. If you are currently on a treatment that is working — keep going. If you are on Opzelura for body vitiligo and frustrated with coverage, this is worth flagging to your dermatologist so they are aware it is coming and can identify you as a candidate when it does become available.
Approval timelines for dermatology indications at the FDA typically run 6–12 months from submission — which puts a possible decision in late 2026 to early 2027, though this is speculative.
The EMA review process typically runs 12-15 months, putting a potential EU decision in mid-to-late 2027. UK MHRA review timelines are similar. If approved, upadacitinib would likely require specialist initiation (rheumatologist or dermatologist) given the monitoring requirements for oral JAK inhibitors.
In the meantime, the treatments that exist and are available now:
